Axogen, Inc. to Report Strong 2024 Financial Results on February 25, 2025

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has announced that it will report its 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. The company will host an investment-community conference call and webcast at 8 a.m. ET following the release.

Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at and clicking on the webcast link. Following the conference call, a replay will be available in the Investors section of the company's website.

Axogen's preliminary unaudited fourth quarter and full-year 2024 key business highlights indicate strong performance across the product portfolio. The company expects fourth quarter revenue to be approximately $49.4 million, representing a 15.1% increase over the fourth quarter of 2023. Full-year 2024 revenue is expected to be approximately $187.3 million, which represents a 17.8% increase over the full-year of 2023.



The positive performance reflects continued improvements in the execution of Axogen's commercial strategies, including a focus on high-potential accounts in Extremities and OMF-Head & Neck applications, adoption of Axogen's complete peripheral nerve surgical algorithm across all procedures, and continued adoption of Resensation® as an expectation for post mastectomy breast reconstruction procedures. The company expects full year gross margin to be above 75.5%, and the total balance of cash, cash equivalents, and investments on December 31, 2024, is expected to be approximately $39.5 million, representing an increase of approximately $2.5 million over that balance at the end of 2023.



Axogen's President and Chief Executive Officer, Michael Dale, stated, "We are pleased with our fourth-quarter and full-year 2024 performance, which reflects continued improvements in effectiveness and efficiency across the business. Looking to the future, on March 4th, 2025, we look forward to hosting an Investor Day at which we will share our strategic priorities for the future and the work we believe will best advance our mission to make peripheral nerve care, standard-of-care for all patients."

Investors and industry observers will be closely watching Axogen's financial results and the company's strategic direction as it continues to innovate and grow in the peripheral nerve repair market. The company's strong performance in 2024 sets the stage for continued success in the coming years.